Pancreatic adenocarcinoma

Current Problems in Cancer

Volumn 20, Issue 5, 1996, Pages 281-328

  Howard, Thomas J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; FEMALE; HUMAN; MALE; PANCREAS TUMOR; REVIEW;

ADENOCARCINOMA; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 0030225625     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0147-0272(96)80001-8     Document Type: Article

References (193)

1. Parker SL, long T. Bolden S, et al. Cancer statistics. 1996. ÇA Cancer J Clin 1996;46:5-27.
2. Grace PA, Pitt HA. Tompkins RK. et al. Decreased morbidity and mortality after pancreaticoduodenectomy. Am J Surg 1986:151:141-9.
3. Trede M, Schwall G, Saeger H. Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447-58.
4. Cameron JL, Pitt HA, Yeo Ci, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430-8.
5. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-73.
6. Maruchi N, Brian D, Ludwig J, et al. Cancer of the pancreas in Olmsted County, Minnesota, 1935-1974. Mayo Clin Proc 1979;54:245-9.
7. Longnecker D. Experimental pancreatic cancer, role of species, sex and diet. Int J Cancer 1990;77:27-38.
8. Fraumeni JF. Cancers of the pancreas and biliary tract. Epidemiological considerations. Cancer Res 1975;35:3437-46.
9. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976;2:1525-36.
10. Hammond EC. Smoking in relation to death rates of one million men and women. Natl Cancer Inst Monogr 1966; 19:127-204.
11. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol 1989;19:208-15.
12. Shibata A, Mack TM, Paganini-Hill A. et al. A prospective study of pancreatic cancer in the elderly. Int J Cancer 1994;58:46-9.
13. Cederlof R, Friberg L, Lundman T. The interaction of smoking, environment and heredity and their implications for disease etiology: a report of epidemiologic studies on the Swedish twin registries. Acta Med Scand 1977;612(supp): 1-128.
14. Whittemore AS, Paffenbarger RS Jr, Anderson K, et al. Early precursors of pancreatic cancer in college men. J Chronic Dis 1983;36:251-6.
15. Huffman D, Masuda Y, Wynder EL. Alpha-naphthylamine and beta-naphylamine in cigarette smoke. Nature 1969;221:255-6.
16. Mack TM, Yu MC, Hanisch R, et al. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986;76:49-60.
17. Mills PK, Beeson WL, Abbey DE, et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988;61:2578-85.
18. Farrow DC, Davis S. Diet and the risk of pancreatic cancer in men. Am J Epidemiol 1990; 132:423-31.
19. La Vecchia C, Negri E, D'Avanzo B. et al. Medical history, diet, and pancreatic cancer. Oncology 1990;47:463-6.
20. Gold EB, Gordis L, Diener M, et al. Diet and other risk factors for cancer of the pancreas. Cancer 1985;55:460-7.
21. Longnecker DS, Roebuck BD, Kuhlmann ET. Enhancement of pancreatic carcinogenesis by a dietary unsaturated fat in rats treated with saline or /V-nitroso(2hydroxypropyl)(2-oxopropyl)amine. J Natl Cancer Inst 1985;74:219-22.
22. Miazza BM, Widgren S, Chayvialle JA, et al. Exocrine pancreatic nodules after long term pancreaticobiliary diversion in rats. An effect of raised CCK plasma concentrations. Gut 1987;28(Suppl):269-74.
23. Roebuck BD. Effect of CCK in the rat model of pancreatic carcinogenesis. Pancreas 1989;4:259-60.
24. Towsend CM Jr, Franklin RB, Watson LC, et al. Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 1981;32:228-30.
25. Pour PM, Hegelson S, Lawson T, et al. Effect of cholecystokinin on pancreatic carcinogenesis in thé hamster model. Carcinogenesis 1988;9:597-601.
26. Everhart J, Wright D. Diabètes mellitus as a risk factor for pancreatic cancer-a meta-analysis. JAMA 1995;273:1605-9.
27. Gullo L, Pezzilli R, Morselli-Labate AM, et al. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331:81-4.
28. O'Mara VA, Byers T. Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985:38:435-41.
29. Jain M, Howe GR, St. Louis P, et al. Coffee and alcohol as determinants of risk of pancreas cancer. A case-control study from Toronto. Int J Cancer 1991;47:384-9.
30. Permert J. Adrian TE, Jacohsson P, et al. Is the peripheral insulin resistance in pancreatic cancer caused by a tumor-associated factor? Am J Surg 1993:165:61-6.
31. Velema JP, Walker AM. Gold EB. Alcohol and pancreatic cancer: insufficient epidemiologic evidence for a causal relationship. Epidemiol Rev 1986;8:28-41.
32. Gold EB. Cameron JL. Chronic pancreatitis and pancreatic cancer. N Engl J Med 1993:328:1485-6.
33. Lowenfels AB. Maisonneuve P. Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993:328:1433-7.
34. Ekbom A, McLaughlin JK, Karlssen B-M, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994;86:625-7.
35. Lynch HT. Genetics and pancreatic cancer. Arch Surg 1994; 129:266-8.
36. Lynch HT, Fusaro L, Lynch JF. Familial pancreatic cancer: a family study. Pancreas 1992:7:511-5.
37. Comfort MW, Steinberg AF. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952:21:54-63.
38. McKusick VA. Mendelian inheritance in man. 10th ed. Baltimore: Johns Hopkins Univ Press, 1992.
39. Lynch HT, Krush AJ, Guirgis H. Genetic factors in families with combined gastrointestinal and breast cancer. Am J Gastroenterol 1973:59:31-40.
40. Lynch HT, Schuelke GS, Kimberling WJ, et al. Hereditary non-polyposis colorectal cancer (Lynch syndromes I and 11). 11. Biomarker studies. Cancer 1985:56:934-8.
41. Lynch HT, Voorhees GJ, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer. A family study. Br J Cancer 1985:52:271-3.
42. Thibodeau SN. Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993:260:816-9.
43. Heimann TM. Miller F, Martinelli G. Significance of DNA content abnormalities in small rectal cancers. Am J Surg 1990:159:199-203.
44. Lynch HT. Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991:6:127-31.
45. ink4 mutations. N Engl J Med 1995:333:970-4.
46. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990:61:759-67.
47. Caldas C. Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994:54:3568-71.
48. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988:53:549-54.
49. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989:49:4682-9.
50. Moodie SA, Wolfman A. The 3Rs of life: ras, rat and growth regulation. Trends Genet 1994:10:37-67.
51. Hall PA, Hughes CM. Staddon SL, et al. The c-crb B-2 proto-oncogene in human pancreatic cancer. J Pathol 1990:161:195-200.
52. Hahn SA, Kern SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995:75:857-69.
53. Kelscr MH. Barkin J, Maclntyre JM. Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 1985:2397-402.
54. Hudis C, Kelsen D, Niedzwiccki D, et al. Pain is not a prominent symptom in most patients with early pancreas cancer. Proc ASCO 1991:10:326.
55. DiMagno EP, Malagelada JR, Taylor WF, et al. A prospective comparison of current diagnostic tests for pancreatic cancer. N Engl J Med 1977:297:737-40.
56. Moosa AR. Diagnosis and treatment of "early" pancreatic cancer. In: Sawyer JL, Williams LF, editors. Difficult problems in general surgery. Chicago: Year Book Medical Publishers, 1989:285-98.
57. Kawarada Y, Yamagisawa K, Isaji S, et al. The prevalence of pancreatic cancer lymph node metastasis in Japan and pancreatic cancer staging categories. Int J Pancreatol 1994:16:101-4.
58. Ariyama J, Suyama M, Ogawa K, et al. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 1990:7:37-47.
59. Satake K, Chung Y-S, Yokomatsu H, et al. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years. Pancreas 1991;6:234-41.
60. Schmiegel W. Tumor markers in pancreatic cancer: current concepts. Hepatogastroenterology 1989;36:446-9.
61. Friess H, Büchler M. Auerbach B, et al. ÇA 494: a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 1993;53:759-63.
62. Rothlin MA, Joller H, Largiader F. ÇA 242 is a new tumor marker for pancreatic cancer. Cancer 1993:71:701-7.
63. Ho SB, Kim YS. Carbohydrate antigens on cancer-associated mucin-like molecules. Semin Cancer Biol 1991:2:389-400.
64. Chung Y-S, Nakata B, Sawada T, et al. New radioimmunoassay for pancreatic cancer associated antigen Span-1 with reference to differential diagnosis and monitoring in pancreatic cancer. Int J Oncol 1993:2:921-6.
65. Van Dyke JA, Stanley RJ, Befiand LL. Pancreatic imaging. Ann Intern Med 1985:102:212-7.
66. Freeny PC, Traverse WL, Ryan JA. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 1993:165: 600-6
67. Wyatt SH, Fishman EK. Spiral CT of the pancreas. Semin Ultrasound CT MR 1994:15:122-32.
68. Thoeni RF, Blankenberg F Pancreatic imaging: computed tomography and magnetic resonance imaging. Radiol Clin North Am 1993:31:1085-113.
69. Megibow AJ, Walsh SJ, Francis IF, et al. Pancreatic adenocarcinoma: CT versus MR imaging in evaluation of resectability; report of the Radiology Diagnostic Oncology Group. Radiology 1995:195:327-32.
70. Freeny PC. Radiologie diagnosis and staging of pancreatic ductal adenocarcinoma. Radiol Clin North Am 1989;27:121-8.
71. Shemesh E, Czerniak A, Nass S, et al. Role of endoscopic retrograde cholangiopancreatography in differentiating pancreatic cancer coexisting with chronic pancreatitis. Cancer 1990:65:893-6.
72. Sawada Y, Gonda H, Hayashida Y. Combined use of brushing cytology and endoscopic retrograde pancreatoaraphy for the early detection of pancreatic cancer. Acta Cytol 1989:33:870-4.
73. Venu RR Geenen JE, Kini M, et al. Endoscopie retrograde brush cytology: a new technique. Gastroenterology 1990:99:1475-9.
74. Lees WR. The pancreas: differential diagnosis and pancreatitis. Gastrointest Endosc Clin N Am 1992:2:657-72.
75. Palazzo L, Roseau G, Gayet V, et al. Endoscopie ultrasonography in adenocarcinoma of the pancreas. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy 1993;25143-50.
76. Rösch T, Baig C, Gain T, et al. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Gastroenterology 1992:102:188-99.
77. Yasuda K, Mukai H. Fujimoto S. et al. The diagnosis of pancreatic cancer by endoscopic ultrasonography. Gastrointest Endosc 1988:34:1-8.
78. Rösch T, Lightdulc CJ, Botet IF. et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992:326:1721-6.
79. Parsons L. Palmet CH. How accurate is fine-needle biopsy in malignant neoplasia of the pancreas? Arch Surg 1989:124:681-3.
80. Al-Kaisi N. Siegler EE. Fine needle aspiration cytology of the pancreas. Acta Cytol 1989:33:145-52.
81. FernandeJ.-del Castillo C. Gonzàlez-Ojeda A. Rcyes E. et al. Tuberculosis of the pancreas. Pancreas 1990:5:693-6.
82. Webb TH, Lillemoe KD, Pitt HA, et al. Pancreatic lymphoma: Is surgery mandatory for diagnosis or treatment? Ann Surg 1989:209:25-30.
83. Warshaw AL. Compton CC. Lewandrowski K. et al. Cystic tumors of the pancreas: new clinical, radiologie, and pathologic observations in 67 patients. Ann Surg 1990:212:432-45.
84. Eckhauser FF. Cheung PS. Vinik AI. et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986:100:978-87.
85. Rashleigh-Belcher HJC. Russell RCG. Lees WR. Cutaneous seeding of pancreatic carcinoma by fine-needle aspiration biopsy. Br J Radiol 1986:59:182-3.
86. Weiss SM. Skibber JM, Mohiuddin M. et al. Rapid intra-abdominal spread of pancreatic cancer. Arch Surg 1985:120:415-6.
87. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991:161:26-30.
88. Yamamoto K. Shibata T. Saji H. et al. Human pancreas scintigraphy using iodine123-labeled HIPDM and SPECT. J Nucl Med 1990:31:1015-9.
89. Baum RP. Imnuinoscintigraphy as a diagnostic tool in pancreatic cancer. Hepatogastroenterology 1989:36:459-61.
90. Lillemoe KD. Sauter P. Pitt HA. et al. Current status of surgical palliation of periampullary carcinoma. Surg Gynecol Obstet 1993:176:1-10.
91. Huibrcgtse K. Katon RM. Coene PP. et al. Endoscopie palliative treatment in pancreatic cancer. Gastrointest Endosc 1986:32:334-8.
92. Cameron JE. Grochow LB. Milligan FD. et al. Pancreatic cancer. In: Pitt HA. CarrLocke DL. Ferrucci JT. editors. Hepatobiliary and pancreatic disease: the team approach to management. New York: Little. Brown. 1995:475-86.
93. American Joint Committee on Cancer. Manual for staging of cancer. Beahrs OH. Henson DE. Hutter RVP, Kennedy B.I. editors. 4th ed. Philadelphia: Lippincott, 1992.
94. Fuhrman CM. Leach SD. Staley ÇA. et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocareinoma adherent to the superior mesentericportal vein confluence. Ann Surg 1996:223:154-62.
95. Manabe T. Su/Aiki T, Tobe T. Evaluation of en bloc radical pancreatectomy for carcinoma of the head of the pancreas involving the adjacent vessels. Dig Surg 1985:2:27-30.
96. Crist DW. Sitzmann JV. Cameron JE. Improved hospital morbidity and mortality after pancreaticoduodenectomy. Am J Surg 1986:151:141-9.
97. Ishikawa O. Ohigashi H, Sasake Y. et al. Practical usefulness of lymphatic and connective tissue clearance for carcinoma of the pancreas head. Ann Surg 1988:208:215-20.
98. Reber HA. Ashley SW. McFadden D. Curative treatment of pancreatic neoplasms: radical resection. Surg Clin North Am 1995:75:905-13.
99. Dooley WC. Cameron JL, Pitt HA. et al. Is preoperative angiography useful in patients with periampullary tumors? Ann Surg 1990:211:649-55.
100. Biehl TR, Traverso LW, Hauptmann E. et al. Preoperative visceral angiography alters intraoperative strategy during the Whipple procedure. Am J Surg 1993:165:607-12.
101. Ward EM, Stephens DH, Sheedy PF 2d. Computed tomographic characteristics of pancreatic carcinoma: an analysis of 100 cases. Radiographies 1983;3:547-65.
102. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg 1986;151:76-80.
103. Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996:223:134-40.
104. Heeckt P, Safi F, Binder T, et al. Free intraperitoneal tumor cells in pancreatic cancer: significance for clinical course and therapy. Chirurg 1992;63:563-7.
105. Juni H, Schott A, Krüger U, et al. Micrometastatic tumor cells are frequently detectable by immunocytology in the peritoneal cavity and bone marrow of pancreatic cancer patients. Int J Pancreatol 1994; 16:259-61.
106. Juhl H, Stritzel M, Wroblewski A. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and bone marrow of gastric, colorectal, and pancreatic cancer patients. Int J Cancer 1994:57:330-5.
107. Kausch W. Das carcinom der papilla duodeni und seine radikale entfernung. Beitr Klin Chirurg 1912;61:728.
108. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935; 102:763-79.
109. Whipple AO. Surgical treatment of carcinoma of the ampullary region and head of the pancreas. Am J Surg 1938;40:260-3.
110. Hunt VC. Surgical management of carcinoma of the ampulla of Vater and of the periampullary portion of duodenum. Ann Surg 1941;114:570-602.
111. Trimble IR, Parsons JW, Sherman CP. A one-stage operation for the cure of carcinoma of the ampulla of Vater and the head of the pancreas. Surg Gynecol Obstet 1941:73:711-22.
112. Cattel RB. A technique for pancreaticoduodenal resection. Surg Clin North Am 1948;28:761-75.
113. Traverse LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959-62.
114. Crue G Jr. The advantages of bypass operations over radical pancreaticoduodenectomy in the treatment of pancreatic cancer. Surg Gynecol Obstet 1970;130:1049-53.
115. Shapiro TM. Adenocarcinoma of the pancreas: a statistical analysis of bypass vs. Whipple resection in good risk patients. Ann Surg 1975:182:715-21.
116. Braasch JW, Deziel DP, Rossi RL, et al. Pyloric and gastric preserving pancreatic resection. Experience with 87 patients. Ann Surg 1986;204:411-8.
117. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards of pancreatic resection in the 1990s. Arch Surg 1995; 130:295-9.
118. McLeod RS, Taylor BR, O'Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995:169:179-85.
119. Cameron JL. Long-term survival following pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas. Surg Clin North Am 1995:75:939-51.
120. Lieberman MD, Kilbum H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638-45.
121. Itani KMF, Coleman RE, Meyers WC, et al. Pylorus-preserving pancreaticoduodenectomy. A clinical and physiologie appraisal. Ann Surg 1986;204: 655-64.
122. Kozuschek W, Rceth HB, Walcczek H. et al. A comparison of long-term results of the standard Whipple procedure and the pylorus-preserving pancreaticoduodenectomy. J Am Coll Surg 1994:178:443-53.
123. Scott HW, Dean RH, Parker T. et al. The role of vagotomy in pancreaticoduodenectomy. Ann Surg 1980:191:688-96.
124. McLeod RS, Taylor BR, O'Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995:169:179-85.
125. Tsao JMI, Rossi RL. Lowell JA. Pylorus-preserving pancreaticoduodenectomy: Is it an adequate cancer operation? Arch Surg 1994:129:405-12.
126. Ihse 1. Lilja P. Arnesjo B, et al. Total pancreatectomy for cancer: an appraisal of 65 cases. Ann Surg 1977:186:675-80.
127. Cuhilla AL. Fortner J. Fitzgerald PJ. Lymph node involvement in carcinoma of the pancreas area. Cancer 1978:41:880-7.
128. van Heerden JA. ReMine WH, Weiland LH. et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas. Am J Surg 1981:142:308-11.
129. Brooks JR. Brooks DC. Levine JD. Total pancreatectomy for ductal cell carcinoma of the pancreas: an update. Ann Surg 1989:209:405-10.
130. Andrén-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983:198:705-10.
131. Nagakawa T, Konishi I, Ueno K, et al. Surgical treatment of pancreatic cancer. The Japanese experience. Int J Pancreatol 1991:9:135-4.3.
132. Gotoh M, Monden M, Sakon M, et al. Intraoperative irradiation in resected carcinoma of the pancreas and portal vein. Arch Surg 1992;127:1213-5.
133. Hiraoka T. Uchino R, Kanemitsu K, et al. Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 1990:7:201-7.
134. OJaki H. Improvement of pancreatic cancer treatment. Int J Pancreatol 1992;12: 5-9.
135. Glasncr S, Longnecker DS, Kalo Y, et al. Comparison of histologie type and stage of exocrine pancreatic neoplasms from surgical scries in Europe. Japan, and the United States. Lab Invest 1992;66:97A.
136. Dobelbower RR. Radiation therapy for cancer of the pancreas alone or combined with surgery and/or chemotherapy: state of the art-1994. Int J Pancreatol 1994:16:294-5.
137. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Cancer Inst 1988:80:751-5.
138. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985:56:2563-8.
139. Dobelbower RR, Wagner SM. Fadell RJ. et al. Pancreatic cancer. In: Dobelbower RR, editor. Gastrointestinal cancer: radiation therapy. Hamburg, Germany: SpringerVerlag, 1990:115-48.
140. Jessup JM. Steele G Jr, Mayer RF, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993:128:559-64.
141. Tepper J, Nardi G. Suit H. Carcinoma of the pancreas: review of MGH experience from 1963-1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1977:37:1519-24.
142. Gastrointestinal Tumor Study Group. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985:120:899-903.
143. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987:59:2006-10.
144. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996;171:118-25.
145. Weese JL, Nussbaum ML, Paul AR, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol 1990;7:177-85.
146. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-9.
147. Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988:61:1110-6.
148. Ozaki H, Kinoshita T, Kosuge T, et al. Effectiveness of multimodality treatment for resectable pancreatic cancer. Int J Pancreatol 1990:7:195-200.
149. Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984;200:289-94.
150. Dobelbower RR Jr, Konski AA, Merrick HW 3d, et al. Intraoperative electron beam radiation therapy (IOEBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys 1991:20:113-9.
151. Mohiuddin M, Rosato F, Barbot D, et al. Long-term results of combined modality treatment with I 125 implantation for carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1992:23:305-11.
152. Order SE, Siegel JS, Lustig RA, et al. Infusional brachytherapy in the treatment of nonresectable pancreatic cancer: a new radiation modality (preliminary report of the phase I study). Antibody Immunoconj Radiopharmacol 1994;7:11-27.
153. Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery 1982:91:123-33.
154. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rad) radiation alone, moderate dose radiation (4000 rad) + 5-fluorouracil, and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
155. Brennan MF, KinsellaTJ, Casper ES. Cancer of the pancreas. De Vita VT Jr, Hellman S, Rosenberg SA, editors. In: Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1993:849-82.
156. Casper ES. Chemotherapy for pancreas cancer: results and mechanism of resistance. Int J Pancreatol 1994; 16:296-8.
157. Wiggins RG, Wooley PV, MacDonald JS, et al. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978:41:387-91
158. Bukowski RM, Aberhalden RT, Hewlett JS, et al. Phase II trial of streptozotocin, mitomycin-C, and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 1980;3:321-4.
159. Bukowski RM, Balcerzak SP, O'Bryan RM, et al. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group Study. Cancer 1983:52:1577-82.
160. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) with 5-fluorouracil, streptozotocin, and mitomycin-C (FSM). Cancer 1986;57: 29-33.
161. Gastrointestinal Tumor Study Group. Phase II studies of drug combination in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C plus fluorouracil. J Clin Oncol 1986;4:1794-8.
162. Buroker T, Kim PN, Groppe C, et al. 5-FU infusion with mitomycin-C vs. 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer A Southwest Oncology Group study. Cancer 1979:44:1215-21.
163. Cullinan SA. Mocrtel CG. Fleming TR. et al. A comparison of chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985:253:2061-7.
164. Rosvold E. Sohilder R. Walczak J, et al. Phase 11 trial of PALA in combination with 5-fluorouraeil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992:29:305-8.
165. Wagner DJTH. Verdonk HER. Dirix LY. et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995:6:129-32.
166. Moore M. Andersen .1. Burris H. et al. A randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer Proc ASCO 1995:14:199(A473l.
167. Rothenberg Ml.. Burris HA 3d. Andersen JS. Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU. Proc ASCO 1995:14:198(A470).
168. Takeda S. Shimajoe T. Sato K, et al. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines. Biochem Biophys Res Comm 1992:14:618-25.
169. Spears CP. Gustax sson BG. Berne M. et al. Mechanisms of innate resistance to thymidylale synthase inhibition after 5-fluonniracil. Cancer Res 1988:48: 5894-900.
170. Greenway BA. Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br J Surg 1987:74:441-2.
171. Kealing JJ. Johnson PJ. Cochrane AMG. et al. A prospective randomized controlled trial of tamoxifen and cyprolerone acetate in pancreatic carcinoma. Br J Cancer 1989:60:789-92.
172. Bakkevold KF. Pettersen A. Arnesjo B. et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990:77: 725-30.
173. Gonzalez-Barcena D. Ibarra-OInios MA. Garcia-Carrasaco F. et al. Influence of D-Trp-6LH-RH on the survival time in patients with advanced pancreatic cancer Biomed Pharmacother 1989:43:313-7.
174. Andren-Sandherg A. Treatment with a L.H-RH analogue in patients with advanced pancreatic cancer. Ada Chir Scand 1990:156:549-5 L
175. Fekcte M. Salatnai A. Schally AV. Presence of membrane binding sites for [DTRP6]-luteini/ing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 1989:45:87-91.
176. Yeo CM. Canieron JL. Lillemoe KD, et al. Paiicreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995:221:721-31.
177. Nitecki SS. Sarr MG. Colby TV. et al. Long term survival after resection for ductal adenocarcinoma of the pancreas: Is it really improving? Ann Surg 1995:221: 59-66.
178. Janes RH. Nicderhuber JE. Chmiel JS. et al. National patterns of care for pancreatic cancer: results of a survey by the Commission on Cancer. Ann Surg 1996:223:261-72.
179. Sarfeh IJ. Rypins KB. JakowatJ. JG. et al. A prospective, randomized clinical investigation of cholecystocntcmstom) and choledochoenterostomy. Am J Surg 1988:155:411-4.
180. Watanapa P. Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1991:79:8-20.
181. S peer AG. Cotton PB. Russell RCG. et al. RandomiJ.ed trial of endoscopic versus percutaneous stem insertion in malignant obstructive jaundice. Lancet 1987:2: 57-62.
182. Andersen JR, Sorensen SM, Kruse A, et al. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989;30:1132-5.
183. Bornman PC, Harries-Jones EP, Tobias R, et al. Prospective controlled trial of transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of the head of the pancreas. Lancet 1986; 1:67-71.
184. Shepard HA, Royle G, Ross APR, et al. Endoscopie biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988;75:1166-8.
185. Dowsett JE, Fussell RCG, Hatfield ARW, et al. Malignant obstructive jaundice: a prospective randomized trial of bypass surgery versus endoscopic stenting. Gastroenterology 1989:96:128A.
186. Doberneck RC, Berndt GA. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 1987; 122:827-9.
187. Rhodes M, Nathanson L, Fielding G. Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas. Gut 1995;36:778-80.
188. Shimi S, Bamtimg S, Cushieri A. Laparoscopy in the management of pancreatic cancer: endoscopic cholecystojejunostomy for advanced disease. Br J Surg 1992;79:317-9.
189. Saltzburg D, Foley KM. Management of pain in pancreatic cancer. Surg Clin North Am 1989;69:629-49.
190. Lebovits A, Lefkowitz M. Pain management of pancreatic carcinoma: a review. Pain 1989;36:1-11.
191. Lee MJ, Mueller PR, vanSonnenberg E, et al. CT-guided celiac ganglion block with alcohol. AJR 1993;161:633-6.
192. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. Ann Surg 1993;217:447-57.
193. Worsey J, Person PF, Keenan RJ, et al. Thoracoscopic pancreatic denervation for pain control in irresectable pancreatic cancer. Br J Surg 1993;80:1051-2.